Showing 2 of 10 years of data. Sign up free for 5 years of history.
View Plans2-year trend showing gross, operating, and net profit margins
J.B. Chemicals & Pharmaceuticals Ltd.'s net profit margin of 16.9% in FY2026 reflects good profitability, with operating margin at 23.4% and gross margin at 69.2%.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd. posted a gross margin of 69.2%, an operating margin of 23.4%, a net margin of 16.9%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
J.B. Chemicals & Pharmaceuticals Ltd.'s revenue grew 7.4% to 42.08B and net profit grew 7.6% to 7.09B YoY in FY2026, indicating moderate business momentum.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd.'s revenue grew by 7.4% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
J.B. Chemicals & Pharmaceuticals Ltd.'s ROE of 17.1% in FY2026 indicates good shareholder returns.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd. reported an ROE of 17.1%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
J.B. Chemicals & Pharmaceuticals Ltd.'s FCF/NI ratio of 0.87x in FY2026 indicates reasonable cash generation relative to profits.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd.'s free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
J.B. Chemicals & Pharmaceuticals Ltd.'s OCF/NI ratio of 0.99x in FY2026 indicates reasonable cash conversion from operations.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd.'s operating cash flow trailed net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
J.B. Chemicals & Pharmaceuticals Ltd.'s current ratio of 4.92x in FY2026 indicates ample liquidity, though assets may be underutilized.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd. reported a current ratio of 4.92. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
J.B. Chemicals & Pharmaceuticals Ltd.'s interest coverage ratio of 176.9x in FY2026 indicates comfortable debt servicing capacity.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd. reported an interest coverage ratio of 176.9x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
J.B. Chemicals & Pharmaceuticals Ltd.'s debt-to-equity ratio of 0.00x in FY2026 reflects a conservative, low-leverage capital structure.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd. reported a debt-to-equity ratio of 0.00. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
J.B. Chemicals & Pharmaceuticals Ltd.'s debt decreased 87.1% YoY in FY2026 — positive deleveraging improves financial flexibility.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd.'s total debt decreased by 87.1% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
J.B. Chemicals & Pharmaceuticals Ltd.'s diluted shares increased 0.6% YoY in FY2026 — share dilution.
Over 2 years (FY2025–FY2026), diluted shares increased 0.6% from 158.69M to 159.62M, indicating cumulative dilution.
In FY 2026, J.B. Chemicals & Pharmaceuticals Ltd.'s diluted shares increased by 0.6% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2026